Cervical Cancer Diagnostic Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Cervical Cancer Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy), By End User (Hospitals & Clinics, Diagnostic Laboratories, Others), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Cervical Cancer Diagnostic Market is projected to grow from USD 8.55 Billion in 2025 to USD 12.52 Billion by 2031, exhibiting a 6.56% CAGR. Cervical cancer diagnostics, encompassing tests like Pap smears and HPV DNA testing, are vital for detecting precancerous lesions and malignancies in the uterine cervix. This market's expansion is primarily fueled by the rising prevalence of cervical cancer and the increasing implementation of government-mandated screening programs, which create a consistent clinical demand for early detection services. For instance, an estimated 13,360 new cases of invasive cervical cancer are anticipated in the United States in 2025, highlighting the critical need for effective diagnostic solutions. A significant challenge, however, impeding market growth is the inadequate healthcare infrastructure and limited financial resources prevalent in developing nations, where the high costs of advanced molecular diagnostic tests restrict their adoption, thereby creating a substantial barrier to widespread advanced screening protocols and limiting the market's overall reach and revenue potential.
Market Driver
The market is fundamentally being reshaped by two key drivers: the advancement of AI-assisted cervical screening algorithms and the widespread implementation of government-mandated national screening programs. AI integration into cytology enhances test accuracy and workflow efficiency by automating the identification of pre-cancerous lesions, thereby reducing human error and increasing laboratory throughput, as exemplified by Hologic, Inc.'s Genius Digital Diagnostics System demonstrating a 28% reduction in false negatives. Simultaneously, public health initiatives aimed at cervical cancer elimination are mobilizing substantial resources, with global commitments like the nearly US$600 million pledged by governments and partners through the World Health Organization in March 2024, to expand vaccine coverage and strengthen screening and treatment programs, ensuring a sustained and policy-driven demand for diagnostic volume, with companies like Roche screening 26.5 million women for cervical cancer risk in 2025.
Market Challenge
A primary restraint on the global cervical cancer diagnostic market is the significant lack of healthcare infrastructure and financial resources in developing nations. The high capital and operational costs associated with advanced molecular tests, despite their accuracy, prevent their adoption in lower-income regions, forcing healthcare providers to rely on less effective, low-cost methods or to forgo screening programs entirely. This economic disparity creates a ceiling for market revenue by effectively excluding a vast demographic from modern diagnostic services and making it challenging for manufacturers to penetrate these markets. The disproportionate burden of the disease in these areas is stark, with the World Health Organization reporting that approximately 94% of global cervical cancer deaths in 2025 occurred in low- and middle-income countries, directly illustrating how financial and infrastructural deficits limit the diagnostic market's reach and commercial scalability.
Market Trends
Two prominent trends are currently reshaping the cervical cancer diagnostic market: the proliferation of at-home and self-sampling HPV collection kits and a fundamental shift towards Human Papillomavirus primary screening guidelines. At-home kits are revolutionizing market access by removing traditional barriers to clinical exams, with regulatory approvals expanding diagnostic reach to populations seeking non-invasive options; for instance, a BD survey in May 2024 found 56% of US women comfortable with self-collected vaginal tests. Concurrently, healthcare authorities are updating protocols to prioritize molecular HPV testing over Pap smears due to its superior sensitivity in identifying precancerous lesions, compelling laboratories to upgrade to molecular platforms. This transition is solidified by recommendations from bodies like the U.S. Preventive Services Task Force, which in December 2024 advised primary HPV screening every five years for women aged 30 to 65.
Key Market Players
* Abbott Laboratories
* Thermo Fisher Scientific Inc
* Becton Dickinson and Company
* Hologic Inc
* CooperSurgical Inc
* Siemens Healthineers AG
* Quigan NV
* F. Hoffmann-La Roche Ltd
* Oncgnostics GmbH
* Quest Diagnostics Inc.
Report Scope
In this report, the Global Cervical Cancer Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Cervical Cancer Diagnostic Market, By Test Type
* Pap testing
* HPV testing
* Colposcopy
* Cervical biopsies
* Cystoscopy
# Cervical Cancer Diagnostic Market, By End User
* Hospitals & Clinics
* Diagnostic Laboratories
* Others
# Cervical Cancer Diagnostic Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Cervical Cancer Diagnostic Market.
Available Customizations:
Global Cervical Cancer Diagnostic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Cervical Cancer Diagnostic Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Test Type (Pap testing, HPV testing, Colposcopy, Cervical biopsies, Cystoscopy)
5.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. North America Cervical Cancer Diagnostic Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Test Type
6.2.2. By End User
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Cervical Cancer Diagnostic Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Test Type
6.3.1.2.2. By End User
6.3.2. Canada Cervical Cancer Diagnostic Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Test Type
6.3.2.2.2. By End User
6.3.3. Mexico Cervical Cancer Diagnostic Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Test Type
6.3.3.2.2. By End User
7. Europe Cervical Cancer Diagnostic Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Test Type
7.2.2. By End User
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Cervical Cancer Diagnostic Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Test Type
7.3.1.2.2. By End User
7.3.2. France Cervical Cancer Diagnostic Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Test Type
7.3.2.2.2. By End User
7.3.3. United Kingdom Cervical Cancer Diagnostic Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Test Type
7.3.3.2.2. By End User
7.3.4. Italy Cervical Cancer Diagnostic Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Test Type
7.3.4.2.2. By End User
7.3.5. Spain Cervical Cancer Diagnostic Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Test Type
7.3.5.2.2. By End User
8. Asia Pacific Cervical Cancer Diagnostic Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Test Type
8.2.2. By End User
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Cervical Cancer Diagnostic Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Test Type
8.3.1.2.2. By End User
8.3.2. India Cervical Cancer Diagnostic Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Test Type
8.3.2.2.2. By End User
8.3.3. Japan Cervical Cancer Diagnostic Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Test Type
8.3.3.2.2. By End User
8.3.4. South Korea Cervical Cancer Diagnostic Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Test Type
8.3.4.2.2. By End User
8.3.5. Australia Cervical Cancer Diagnostic Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Test Type
8.3.5.2.2. By End User
9. Middle East & Africa Cervical Cancer Diagnostic Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Test Type
9.2.2. By End User
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Cervical Cancer Diagnostic Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Test Type
9.3.1.2.2. By End User
9.3.2. UAE Cervical Cancer Diagnostic Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Test Type
9.3.2.2.2. By End User
9.3.3. South Africa Cervical Cancer Diagnostic Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Test Type
9.3.3.2.2. By End User
10. South America Cervical Cancer Diagnostic Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Test Type
10.2.2. By End User
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Cervical Cancer Diagnostic Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Test Type
10.3.1.2.2. By End User
10.3.2. Colombia Cervical Cancer Diagnostic Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Test Type
10.3.2.2.2. By End User
10.3.3. Argentina Cervical Cancer Diagnostic Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Test Type
10.3.3.2.2. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Cervical Cancer Diagnostic Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Abbott Laboratories
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Thermo Fisher Scientific Inc
15.3. Becton Dickinson and Company
15.4. Hologic Inc
15.5. CooperSurgical Inc
15.6. Siemens Healthineers AG
15.7. Quigan NV
15.8. F. Hoffmann-La Roche Ltd
15.9. Oncgnostics GmbH
15.10. Quest Diagnostics Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們